Riskpilot← Back to searchSign inGet full accessChristina PV-Pharma Consulting AB
ABActiveOrg 5593975583Karlfeldtsgatan 10 Lgh 1101Research and experimental development on natural sciences and engineering · NACE 7210Est. 20222 employees
Revenue 2025
SEK 3,1M
-31% vs 2024
EBITDA margin
84.4%
-38% vs 2024
Equity ratio
60.1%
Financial strength
Net profit 2025
SEK 1,6M
-38% vs 2024
| Revenue | SEK 3,1M | -31% |
| EBITDA | SEK 2,6M | -38% |
| Net profit | SEK 1,6M | -38% |
| Total assets | SEK 6M | +38% |
| Equity | SEK 3,6M | +33% |
| Employees | 2 | — |
Legal name
Christina PV-Pharma Consulting AB
Org number
5593975583
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20 september 2022
Share capital
SEK 25 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva konsultverksamhet och utbildning inom farmakovigilans, biverkningshantering samt därmed förenlig verksamhet. Föremål för bolagets verksamhet är att äga och förvalta lös respektive fast egendom samt bedriva därmed förenlig verksamhet.
Address
Karlfeldtsgatan 10 Lgh 1101
Email
christina.strommoller@pvpharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 257 | 4 472 | 3 079 |
| Staff expenses | — | −9 | −200 |
| EBITDA | 210 | 4 220 | 2 597 |
| Depreciation & amort. | — | — | — |
| EBIT | 210 | 4 220 | 2 597 |
| Net financials | 0 | 1 | 20 |
| Profit before tax | 210 | 3 166 | 1 968 |
| Tax | −44 | −652 | −409 |
| Net profit | 166 | 2 514 | 1 558 |
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 327 | 4 379 | 6 028 |
| Equity | 201 | 2 715 | 3 621 |
| Long-term debt | — | — | — |
| Short-term debt | 126 | 609 | 702 |
| Total debt | 126 | 609 | 702 |
EBITDA margin
84.4%
This company
15.8%
Market median
+434% vs market
20232025
Equity ratio
60.1%
This company
38.2%
Market median
+57% vs market
20232025
Return on equity
43.0%
This company
18.4%
Market median
+134% vs market
20232025
Net profit margin
50.6%
This company
8.1%
Market median
+525% vs market
20232025
Asset turnover
0.51×
This company
1.12×
Market median
-54% vs market
20232025
Debt / equity
0.66×
This company
0.62×
Market median
+6% vs market
20232025
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (4) | ||
| Chairman | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Christina PV-Pharma Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| M H Charlotte Wiberg Larsson | Chairman | 0 companies |
| Bo Torsten Nilsson | Board of Directors | 0 companies |
| Alma Christina Ström Möller | Board of Directors | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Selma Margareta Möller Graca | Deputy Board Member | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |